Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Khalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A Philip, Bassel El-Rayes, Boris C Pasche, Asfar S Azmi · 2025
Read Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges by Khalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A Philip, Bassel El-Rayes, Boris C Pasche, Asfar S Azmi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12660860.txt.
Description
Khalil Choucair and eight co-authors review the hunt for drugs against KRAS, a cancer driver gene, in this twenty twenty-five paper. Faulty KRAS is the most common cancer switch in solid tumors and was long called undruggable. Two drugs that block one form of the fault are now approved for lung cancer.
Those drugs help only a share of patients, and resistance soon follows. Other KRAS faults, which drive harsh cancers like pancreatic cancer, still have no targeted drug. The review pulls together gains in gene signaling, RNA drugs, and tumor surroundings. It maps the next steps toward wider, longer-lasting control of this driver.
Catalog record
| CREATOR | Khalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A Philip, Bassel El-Rayes, Boris C Pasche, Asfar S Azmi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 141 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |